Abstract
The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Current Drug Delivery
Title: Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Volume: 8 Issue: 3
Author(s): Ryan W. Hung, Samar Hamdy, Azita Haddadi, Zahra Ghotbi and Afsaneh Lavasanifar
Affiliation:
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Abstract: The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Export Options
About this article
Cite this article as:
W. Hung Ryan, Hamdy Samar, Haddadi Azita, Ghotbi Zahra and Lavasanifar Afsaneh, Part II: Targeted Particles for Imaging of Anticancer Immune Responses, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256219
DOI https://dx.doi.org/10.2174/156720111795256219 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Taking Cell Culture in Drug Discovery to the Third Dimension - A Patent Review
Recent Patents on Biomedical Engineering (Discontinued) Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Strategies for Targeting Lentiviral Vectors
Current Gene Therapy PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Transposons for Gene Therapy!
Current Gene Therapy Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets Cancer-Targeting Multifunctionalized Gold Nanoparticles in Imaging and Therapy
Current Medicinal Chemistry Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design